Abstract
Recent efforts have revealed that numerous protein-coding messenger RNAs have natural antisense transcript partners, most of which seem to be noncoding RNAs. Here we identify a conserved noncoding antisense transcript for β-secretase-1 (BACE1), a crucial enzyme in Alzheimer's disease pathophysiology. The BACE1-antisense transcript (BACE1-AS) regulates BACE1 mRNA and subsequently BACE1 protein expression in vitro and in vivo. Upon exposure to various cell stressors including amyloid-β 1–42 (Aβ 1–42), expression of BACE1-AS becomes elevated, increasing BACE1 mRNA stability and generating additional Aβ 1–42 through a post-transcriptional feed-forward mechanism. BACE1-AS concentrations were elevated in subjects with Alzheimer's disease and in amyloid precursor protein transgenic mice. These data show that BACE1 mRNA expression is under the control of a regulatory noncoding RNA that may drive Alzheimer's disease–associated pathophysiology. In summary, we report that a long noncoding RNA is directly implicated in the increased abundance of Aβ 1–42 in Alzheimer's disease.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Goedert, M. & Spillantini, M.G. A century of Alzheimer's disease. Science 314, 777–781 (2006).
Faghihi, M.A., Mottagui-Tabar, S. & Wahlestedt, C. Genetics of neurological disorders. Expert Rev. Mol. Diagn. 4, 317–332 (2004).
Monaco, S., Zanusso, G., Mazzucco, S. & Rizzuto, N. Cerebral amyloidoses: molecular pathways and therapeutic challenges. Curr. Med. Chem. 13, 1903–1913 (2006).
Lacor, P.N. et al. Aβ oligomer–induced aberrations in synapse composition, shape, and density provide a molecular basis for loss of connectivity in Alzheimer's disease. J. Neurosci. 27, 796–807 (2007).
Zhu, D. et al. Phospholipases A2 mediate amyloid-β peptide–induced mitochondrial dysfunction. J. Neurosci. 26, 11111–11119 (2006).
Esposito, G. et al. CB1 receptor selective activation inhibits β-amyloid–induced iNOS protein expression in C6 cells and subsequently blunts tau protein hyperphosphorylation in co-cultured neurons. Neurosci. Lett. 404, 342–346 (2006).
Snyder, E.M. et al. Regulation of NMDA receptor trafficking by amyloid-β. Nat. Neurosci. 8, 1051–1058 (2005).
Matsuyama, S., Teraoka, R., Mori, H. & Tomiyama, T. Inverse correlation between amyloid precursor protein and synaptic plasticity in transgenic mice. Neuroreport 18, 1083–1087 (2007).
Abramov, A.Y., Canevari, L. & Duchen, M.R. β-amyloid peptides induce mitochondrial dysfunction and oxidative stress in astrocytes and death of neurons through activation of NADPH oxidase. J. Neurosci. 24, 565–575 (2004).
Ohyagi, Y. et al. Intracellular Aβ42 activates p53 promoter: a pathway to neurodegeneration in Alzheimer's disease. FASEB J. 19, 255–257 (2005).
Zhao, J. et al. β-site amyloid precursor protein cleaving enzyme 1 levels become elevated in neurons around amyloid plaques: implications for Alzheimer's disease pathogenesis. J. Neurosci. 27, 3639–3649 (2007).
Sun, X. et al. Hypoxia facilitates Alzheimer's disease pathogenesis by up-regulating BACE1 gene expression. Proc. Natl. Acad. Sci. USA 103, 18727–18732 (2006).
Tong, Y. et al. Oxidative stress potentiates BACE1 gene expression and Aβ generation. J. Neural Transm. 112, 455–469 (2005).
Li, R. et al. Amyloid β peptide load is correlated with increased β-secretase activity in sporadic Alzheimer's disease patients. Proc. Natl. Acad. Sci. USA 101, 3632–3637 (2004).
Holsinger, R.M., McLean, C.A., Collins, S.J., Masters, C.L. & Evin, G. Increased β-secretase activity in cerebrospinal fluid of Alzheimer's disease subjects. Ann. Neurol. 55, 898–899 (2004).
Fukumoto, H., Cheung, B.S., Hyman, B.T. & Irizarry, M.C. β-secretase protein and activity are increased in the neocortex in Alzheimer disease. Arch. Neurol. 59, 1381–1389 (2002).
Johnston, J.A. et al. Expression and activity of β-site amyloid precursor protein cleaving enzyme in Alzheimer's disease. Biochem. Soc. Trans. 33, 1096–1100 (2005).
Ohno, M. et al. BACE1 deficiency rescues memory deficits and cholinergic dysfunction in a mouse model of Alzheimer's disease. Neuron 41, 27–33 (2004).
Tesco, G. et al. Depletion of GGA3 stabilizes BACE and enhances β-secretase activity. Neuron 54, 721–737 (2007).
Ma, H. et al. Involvement of β-site APP cleaving enzyme 1 (BACE1) in amyloid precursor protein–mediated enhancement of memory and activity-dependent synaptic plasticity. Proc. Natl. Acad. Sci. USA 104, 8167–8172 (2007).
Laird, F.M. et al. BACE1, a major determinant of selective vulnerability of the brain to amyloid-β amyloidogenesis, is essential for cognitive, emotional, and synaptic functions. J. Neurosci. 25, 11693–11709 (2005).
Hu, X. et al. Bace1 modulates myelination in the central and peripheral nervous system. Nat. Neurosci. 9, 1520–1525 (2006).
Willem, M. et al. Control of peripheral nerve myelination by the β-secretase BACE1. Science 314, 664–666 (2006).
Engstrom, P.G. et al. Complex loci in human and mouse genomes. PLoS Genet. 2, e47 (2006).
Katayama, S. et al. Antisense transcription in the mammalian transcriptome. Science 309, 1564–1566 (2005).
Wahlestedt, C. Natural antisense and noncoding RNA transcripts as potential drug targets. Drug Discov. Today 11, 503–508 (2006).
Su, Y., Ryder, J. & Ni, B. Inhibition of Aβ production and APP maturation by a specific PKA inhibitor. FEBS Lett. 546, 407–410 (2003).
Thakker, D.R., Hoyer, D. & Cryan, J.F. Interfering with the brain: use of RNA interference for understanding the pathophysiology of psychiatric and neurological disorders. Pharmacol. Ther. 109, 413–438 (2006).
Borghi, R. et al. The increased activity of BACE1 correlates with oxidative stress in Alzheimer's disease. Neurobiol. Aging 28, 1009–1014 (2006).
Tamagno, E., Bardini, P., Guglielmotto, M., Danni, O. & Tabaton, M. The various aggregation states of β-amyloid 1–42 mediate different effects on oxidative stress, neurodegeneration, and BACE-1 expression. Free Radic. Biol. Med. 41, 202–212 (2006).
Harkany, T. et al. Mechanisms of β-amyloid neurotoxicity: perspectives of pharmacotherapy. Rev. Neurosci. 11, 329–382 (2000).
Yatin, S.M. et al. Temporal relations among amyloid β-peptide–induced free-radical oxidative stress, neuronal toxicity, and neuronal defensive responses. J. Mol. Neurosci. 11, 183–197 (1998).
Meyer-Luehmann, M. et al. Rapid appearance and local toxicity of amyloid-β plaques in a mouse model of Alzheimer's disease. Nature 451, 720–724 (2008).
Walsh, D.M. et al. The role of cell-derived oligomers of Aβ in Alzheimer's disease and avenues for therapeutic intervention. Biochem. Soc. Trans. 33, 1087–1090 (2005).
Link, C.D. et al. Gene expression analysis in a transgenic Caenorhabditis elegans Alzheimer's disease model. Neurobiol. Aging 24, 397–413 (2003).
Ray, S. et al. Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins. Nat. Med. 13, 1359–1362 (2007).
Chishti, M.A. et al. Early-onset amyloid deposition and cognitive deficits in transgenic mice expressing a double mutant form of amyloid precursor protein 695. J. Biol. Chem. 276, 21562–21570 (2001).
Li, F. et al. Increased plaque burden in brains of APP mutant MnSOD heterozygous knockout mice. J. Neurochem. 89, 1308–1312 (2004).
McConlogue, L. et al. Partial reduction of BACE1 has dramatic effects on Alzheimer plaque and synaptic pathology in APP transgenic mice. J. Biol. Chem. 282, 26326–26334 (2007).
Zhong, Z. et al. Levels of β-secretase (BACE1) in cerebrospinal fluid as a predictor of risk in mild cognitive impairment. Arch. Gen. Psychiatry 64, 718–726 (2007).
Li, Y., Zhou, W., Tong, Y., He, G. & Song, W. Control of APP processing and Aβ generation level by BACE1 enzymatic activity and transcription. FASEB J. 20, 285–292 (2006).
Cirrito, J.R. et al. Synaptic activity regulates interstitial fluid amyloid-β levels in vivo. Neuron 48, 913–922 (2005).
Emilsson, L., Saetre, P. & Jazin, E. Alzheimer's disease: mRNA expression profiles of multiple patients show alterations of genes involved with calcium signaling. Neurobiol. Dis. 21, 618–625 (2006).
Brooks, W.M. et al. Gene expression profiles of metabolic enzyme transcripts in Alzheimer's disease. Brain Res. 1127, 127–135 (2007).
Rossner, S., Sastre, M., Bourne, K. & Lichtenthaler, S.F. Transcriptional and translational regulation of BACE1 expression–implications for Alzheimer's disease. Prog. Neurobiol. 79, 95–111 (2006).
Holsinger, R.M., McLean, C.A., Beyreuther, K., Masters, C.L. & Evin, G. Increased expression of the amyloid precursor β-secretase in Alzheimer's disease. Ann. Neurol. 51, 783–786 (2002).
Hsieh, H. et al. AMPAR removal underlies Aβ-induced synaptic depression and dendritic spine loss. Neuron 52, 831–843 (2006).
St Laurent, G., III & Wahlestedt, C. Noncoding RNAs: couplers of analog and digital information in nervous system function? Trends Neurosci. 30, 612–621 (2007).
Vassar, R. The β-secretase, BACE: a prime drug target for Alzheimer's disease. J. Mol. Neurosci. 17, 157–170 (2001).
Kumar, P. et al. Transvascular delivery of small interfering RNA to the central nervous system. Nature 448, 39–43 (2007).
Acknowledgements
We thank J. Rogers (Sun Health Research Institute) for autopsy brain tissue. We are grateful to M. Leissring (Mayo Clinic) for helpful discussions and for kindly providing cell lines and APP- tg19959 mouse materials. We also thank D. Willoughby for his help in RNA purification from human Alzheimer's disease samples. S. Brothers provided valuable help in manuscript preparation. M.A.F. is partly supported by a scholarship from the Ahwaz University of Medical Sciences, Ministry of Health I.R. Iran. This study has been supported in part by the US National Institutes of Health (AG 029290).
Author information
Authors and Affiliations
Contributions
C.W., M.A.F., P.J.K. and G.S.L. conceived and designed the experiments and analyzed the data. M.A.F., F.M., P.J.K. and A.M.K. performed the experiments. D.E.W., B.G.S., T.E.M. and C.E.F. provided human Alzheimer's disease RNA samples. M.A.F., C.W., P.J.K. and G.S.L. wrote the paper.
Corresponding author
Supplementary information
Supplementary Text and Figures
Supplementary Figs. 1–6, Supplementary Data 1 and 2, Supplementary Table 1 and Supplementary Methods (PDF 3081 kb)
Rights and permissions
About this article
Cite this article
Faghihi, M., Modarresi, F., Khalil, A. et al. Expression of a noncoding RNA is elevated in Alzheimer's disease and drives rapid feed-forward regulation of β-secretase. Nat Med 14, 723–730 (2008). https://doi.org/10.1038/nm1784
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/nm1784
This article is cited by
-
Ferroptosis regulation through Nrf2 and implications for neurodegenerative diseases
Archives of Toxicology (2024)
-
Integrative Analysis of the Age-Related Dysregulated Genes Reveals an Inflammation and Immunity-Associated Regulatory Network in Alzheimer’s Disease
Molecular Neurobiology (2024)
-
Alzheimer’s Disease-Related Epigenetic Changes: Novel Therapeutic Targets
Molecular Neurobiology (2024)
-
Role of long non-coding RNAs in the pathophysiology of Alzheimer’s disease and other dementias
Molecular Biology Reports (2024)
-
Association filtering and generative adversarial networks for predicting lncRNA-associated disease
BMC Bioinformatics (2023)